Minimal important difference in field walking tests in non-cystic fibrosis bronchiectasis following exercise training

Lee, Annemarie L.; Hill, Catherine J.; Cecins, Nola; Jenkins, Sue; McDonald, Christine F; Burge, Angela T; Rautela, Linda; Stirling, Robert; Thompson, Philip J.; Holland, Anne E

doi:10.1016/j.rmed.2014.07.006

Cited by 40 publications

(34 citation statements)

References 43 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Database searches, handsearches, and consultation with an expert yielded 39 potentially relevant articles. After reviews of their titles, abstracts, and full text, 6 were found appropriate for inclusion in our review . Table summarizes the studies.…”

Section: Resultsmentioning

confidence: 99%

“…The anchor‐based MCID is well established as an indicator of such change, and ROC analysis is considered to be a superior approach for determining MCIDs . Although numerous MCIDs for the 6MWT have been proposed, we believe that ours is the first systematic review of MCIDs for the 6MWT determined by ROC analysis. Although our review was focused on MCIDs so determined, it is validating that MCIDs calculated by others who used regression analysis (14.0‐35.4 m) are within the range we reported.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Minimal clinically important difference for change in 6‐minute walk test distance of adults with pathology: a systematic review

Bohannon

Crouch

2016

Evaluation Clinical Practice

420

282

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 97%

Minimal clinically important difference for change in 6‐minute walk test distance of adults with pathology: a systematic review

Bohannon

Crouch

2016

Evaluation Clinical Practice

420

282

View full text Add to dashboard Cite

show abstract

“…4Absolute six-minute walk test (6MWT) minimal clinically important difference (MCID) using distribution-based methods. Sources: 1 & 2 = du Bois, 2010 [29] and du Bois, 2011 [30]; 3 = Swigris, 2010 [31]; 4 = Holland, 2009 [42]; 5 = Holland, 2010 [43]; 7 = Puhan, 2008 [51]; 8 = Puhan, 2011 [44]; 10 = Wise, 2005 [52]; 11 = Lee, 2014 [46]; 12 & 13 = Gremeaux, 2011 [47] and Gremeaux, 2011 [48]; 14 = Gilbert, 2009 [53]; 15 = Mathai, 2012 [49]; 17 = McDonald, 2013 [54]; 18 = Kwok, 2013 [50]. The green , red , blue , and orange bars represent studies conducted in patients with respiratory, cardiovascular, muscular, and other (i.e., frail elderly) diseases, respectively.…”

Section: Resultsmentioning

confidence: 99%

Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome

Schrover¹,

Evans²,

Giugliani

et al. 2017

Orphanet J Rare Dis

View full text Add to dashboard Cite

Morquio A syndrome is an ultra-rare, inherited lysosomal storage disorder associated with progressive, multi-systemic clinical impairments, causing gradual loss of functional capacity and endurance, impaired quality of life, and early mortality. Studies in Morquio A patients have used the 6-min walk test (6MWT) to assess functionality and endurance and to evaluate disease progression or efficacy of treatment. The objective of the present study was to review minimal clinically important differences (MCIDs) for the 6MWT reported for disease states that widely use the 6MWT to evaluate clinical benefit and to discuss the results in view of the challenges in estimating MCID for ultra-rare diseases, using the case of elosulfase alfa in Morquio A patients. A systematic literature search was performed using Embase and Medline to identify studies specifically estimating the MCID using either anchor-based or distribution-based methods. A total of 19 publications on 17 studies were identified; none of these included patients with Morquio A syndrome or the wider disease category of lysosomal storage disorders. Therefore, the MCIDs determined by studies in patients with respiratory, cardiovascular, or musculoskeletal disease were compared to changes in the 6MWT seen in Morquio A patients in the pivotal phase 3 clinical trial of elosulfase alfa enzyme replacement therapy. The literature review showed a mean MCID for the 6MWT of 7% change (range 3–15%) in studies using anchor-based methods and a 9% change (range 4–16%) using distribution-based methods. Results of the elosulfase alfa clinical trial and its extension showed a placebo-adjusted 14.9% improvement in the 6MWT from baseline at week 24, which was greater than the mean MCID based on the results of the systematic literature review. After 2 years, 6MWT distance increased by a mean of 20.7% from baseline in a modified per-protocol population, versus a reduction of 6.9% in comparable untreated patients from the MorCAP natural history study over the same period. Although further research is required to establish the MCID of the 6MWT in Morquio A patients, the presented data provide further evidence for the positive effect of elosulfase alfa in this patient population.Electronic supplementary materialThe online version of this article (doi:10.1186/s13023-017-0633-1) contains supplementary material, which is available to authorized users.

show abstract

“…In addition, a minimal important difference has been estimated for the 6MWT (25 m) and ISWT (35 m) in bronchiectasis (Lee et al ). 221 Therefore, these are suitable outcome measures to assess exercise capacity before and after PR in the bronchiectasis population.…”

Section: Sectionmentioning

confidence: 99%

“…As in other respiratory disease, exercise capacity can be assessed using 6MWD or ISWT and even small changes in these measures may reflect important changes in health. 221 …”

Section: Section 15mentioning

confidence: 99%

British Thoracic Society Guideline for bronchiectasis in adults

Hill

Sullivan

Chalmers

et al. 2018

Thorax

314

281

View full text Add to dashboard Cite

Minimal important difference in field walking tests in non-cystic fibrosis bronchiectasis following exercise training

Abstract: Small changes in 6MWD and ISWD may represent clinically important benefits in people with non-CF bronchiectasis. These data are likely to assist in the interpretation of change in exercise capacity following intervention.

Cited by 40 publications

References 43 publications

Minimal clinically important difference for change in 6‐minute walk test distance of adults with pathology: a systematic review

Minimal clinically important difference for change in 6‐minute walk test distance of adults with pathology: a systematic review

Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome

British Thoracic Society Guideline for bronchiectasis in adults

Contact Info

Product

Resources

About